Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences
Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on developing targeted oncology therapies, has announced its participation in two upcoming investor conferences.
Brian Sullivan, Chief Executive Officer and Co-founder of Celcuity, will represent the company at both events where he will present and be available for one-on-one investor meetings.
The first appearance will be a fireside chat at the TD Cowen 45th Annual Health Care Conference in Boston on Tuesday, March 4, 2025, at 10:30 a.m. ET. The second presentation will take place at the Leerink Global Healthcare Conference 2025 in Miami on Wednesday, March 12, 2025, at 9:20 a.m. ET.
Live webcasts of both presentations will be available through dedicated weblinks provided in the announcement.
Celcuity Inc. (Nasdaq: CELC), una società biotecnologica in fase clinica focalizzata sullo sviluppo di terapie oncologiche mirate, ha annunciato la sua partecipazione a due prossime conferenze per investitori.
Brian Sullivan, Amministratore Delegato e Co-fondatore di Celcuity, rappresenterà l'azienda in entrambi gli eventi, dove presenterà e sarà disponibile per incontri individuali con gli investitori.
La prima apparizione sarà una chiacchierata informale alla 45ª Conferenza Annuale sulla Salute di TD Cowen a Boston martedì 4 marzo 2025, alle 10:30 ET. La seconda presentazione si terrà alla Conferenza Globale sulla Salute 2025 di Leerink a Miami mercoledì 12 marzo 2025, alle 9:20 ET.
Le dirette web di entrambe le presentazioni saranno disponibili tramite link web dedicati forniti nell'annuncio.
Celcuity Inc. (Nasdaq: CELC), una empresa de biotecnología en etapa clínica centrada en el desarrollo de terapias oncológicas dirigidas, ha anunciado su participación en dos próximas conferencias para inversores.
Brian Sullivan, Director Ejecutivo y Co-fundador de Celcuity, representará a la compañía en ambos eventos, donde presentará y estará disponible para reuniones individuales con los inversores.
La primera aparición será una charla informal en la 45ª Conferencia Anual de Salud de TD Cowen en Boston el martes 4 de marzo de 2025, a las 10:30 a.m. ET. La segunda presentación tendrá lugar en la Conferencia Global de Atención Médica 2025 de Leerink en Miami el miércoles 12 de marzo de 2025, a las 9:20 a.m. ET.
Las transmisiones en vivo de ambas presentaciones estarán disponibles a través de enlaces web dedicados proporcionados en el anuncio.
Celcuity Inc. (Nasdaq: CELC)는 표적 항암 치료제를 개발하는 임상 단계의 생명공학 회사로, 두 개의 다가오는 투자자 회의에 참여한다고 발표했습니다.
Celcuity의 CEO이자 공동 창립자인 Brian Sullivan이 두 행사에서 회사를 대표하며, 발표를 하고 투자자와의 일대일 미팅도 진행할 예정입니다.
첫 번째 일정은 2025년 3월 4일 화요일 오전 10:30 ET에 보스턴에서 열리는 TD Cowen 제45회 연례 건강 관리 회의에서의 대담입니다. 두 번째 발표는 2025년 3월 12일 수요일 오전 9:20 ET에 마이애미에서 열리는 Leerink 글로벌 건강 관리 회의 2025에서 진행됩니다.
두 발표의 생중계는 발표에서 제공된 전용 웹 링크를 통해 이용할 수 있습니다.
Celcuity Inc. (Nasdaq: CELC), une entreprise de biotechnologie en phase clinique axée sur le développement de thérapies oncologiques ciblées, a annoncé sa participation à deux prochaines conférences pour investisseurs.
Brian Sullivan, Directeur Général et Co-fondateur de Celcuity, représentera l'entreprise lors des deux événements, où il fera une présentation et sera disponible pour des réunions individuelles avec les investisseurs.
La première apparition sera une discussion informelle lors de la 45e Conférence Annuelle sur la Santé de TD Cowen à Boston, le mardi 4 mars 2025, à 10h30 ET. La deuxième présentation aura lieu lors de la Conférence Mondiale sur la Santé 2025 de Leerink à Miami, le mercredi 12 mars 2025, à 9h20 ET.
Des webdiffusions en direct des deux présentations seront disponibles via des liens web dédiés fournis dans l'annonce.
Celcuity Inc. (Nasdaq: CELC), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung gezielter Onkologie-Therapien konzentriert, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt.
Brian Sullivan, Chief Executive Officer und Mitbegründer von Celcuity, wird das Unternehmen bei beiden Veranstaltungen vertreten, wo er präsentieren und für Einzelgespräche mit Investoren zur Verfügung stehen wird.
Der erste Auftritt wird ein informelles Gespräch auf der 45. jährlichen Gesundheitskonferenz von TD Cowen in Boston am Dienstag, den 4. März 2025, um 10:30 Uhr ET sein. Die zweite Präsentation findet am Mittwoch, den 12. März 2025, um 9:20 Uhr ET auf der Leerink Global Healthcare Conference 2025 in Miami statt.
Live-Übertragungen beider Präsentationen werden über spezielle Weblinks bereitgestellt, die in der Ankündigung enthalten sind.
- None.
- None.
MINNEAPOLIS, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences:
- A fireside chat at the TD Cowen 45th Annual Health Care Conference in Boston at 10:30 a.m. ET on Tuesday, March 4, 2025. A live webcast will be available using this weblink: https://wsw.com/webcast/cowen177/celc/1986573; and
- A fireside chat at the Leerink Global Healthcare Conference 2025 in Miami at 9:20 a.m. ET on Wednesday, March 12, 2025. A live webcast will be available using this weblink: https://wsw.com/webcast/leerink38/celc/2182307
About Celcuity
Celcuity is a clinical-stage biotechnology company focused on development of targeted therapies for treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. More detailed information about the VIKTORIA-1 study can be found at ClinicalTrials.gov. A Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is on-going. A Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer is expected to begin enrolling patients in the second quarter of 2025. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com. Follow us on LinkedIn and Twitter.
View source version of release on GlobeNewswire.com
Contacts:
Celcuity Inc.
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com
(763) 392-0123
ICR Healthcare
Patti Bank, patti.bank@icrhealthcare.com
(415) 513-1284
FAQ
When is Celcuity (CELC) presenting at the TD Cowen Health Care Conference?
Will Celcuity (CELC) provide a webcast of their investor conference presentations?
Which investor conferences will Celcuity (CELC) participate in during March 2025?
Who will represent Celcuity (CELC) at the upcoming investor conferences?
What time is Celcuity's (CELC) presentation at the Leerink Global Healthcare Conference?
